Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
In a world overrun by innovative biotechs, be a Mammoth Biosciences. Or a Nutcracker Therapeutics. Or Viking Therapeutics or Centessa Pharmaceuticals. I could go on and on and on with creative names of companies in this industry that are vibrant, fun and eye-catching. But most importantly, they make you overlook the potential scientific language barrier, the potential to not exactly understand what the company is doing at all, and make you want to learn more anyway.
The COVID pandemic was a make or break moment for many a biotech. At Mammoth Biosciences, it may have been a little of both. For Janice Chen, Ph.D., the CRISPR biotech's chief technology officer and co-founder who ventured out of her lab and into the C-suite in 2018, the whole journey has been wild.
Mammoth Biosciences is taking a big step away from its original ambition of upending the diagnostics business with CRISPR, and has laid off the bulk of its employees working on testing.
BRISBANE, Calif.--(BUSINESS WIRE)--Mammoth Biosciences, Inc., a biotechnology company building the next generation of CRISPR products with a mission to cure and detect diseases, today announced the appointment of Phil Tinmouth as Chief Business Officer and Siang Chin as General Counsel.
Mammoth Biosciences Named to Fast Company’s 2022 List of the Next Big Things in Tech
Mammoth Biosciences Named in BioSpace’s 2023 Best Places to Work
BRISBANE, Calif.--(BUSINESS WIRE)--Mammoth Biosciences, a biotech company harnessing next-generation CRISPR technology to detect and cure disease, has been chosen by Endpoints News Editor John Carroll as one of the most promising biotech startups for this year’s Endpoints 11 annual special report.
BRISBANE, Calif.--(BUSINESS WIRE)--Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, today announced the appointment of Elaine Sun as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
BRISBANE, Calif.--(BUSINESS WIRE)--Mammoth Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST® SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.